Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
All content for On The Pen With Dave Knapp is the property of Bleav, Dave Knapp Founder of On The Pen and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
Is Wegovy Better Than Zepbound? Plus the First Obesity GLP-1 Generic is Here!
On The Pen With Dave Knapp
26 minutes 1 second
2 months ago
Is Wegovy Better Than Zepbound? Plus the First Obesity GLP-1 Generic is Here!
This episode of On The Pen: The Weekly Dose Podcast breaks down four major stories in obesity medicine: the FDA’s approval of Teva’s so-called “generic” Saxenda at a sky-high price, Wegovy’s accelerated approval in MASH, Novo Nordisk’s headline-grabbing but shaky 57% cardiovascular benefit claim, and Eli Lilly’s decision to scrap its oral GLP-1 naperiglipron. We cut through the spin to ask what these developments really mean for patients fighting for access and better treatment options.
On The Pen With Dave Knapp
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
